Nifty
:
14581.45
Sensex
:
48803.68
76.65 (0.53%)
259.62 (0.53%)
Nifty
Sensex
:
:
14581.45
48803.68
76.65 (0.53%)
259.62 (0.53%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
633.25
15-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  633.60
  •  641.50
  •  626.50
  •  627.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  8588761
  •  54551.92
  •  654.40
  •  434.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 151,865.91
  • 63.03
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 153,693.24
  • 0.63%
  • 3.23

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 3.31%
  • 7.20%
  • FII
  • DII
  • Others
  • 12.19%
  • 20.11%
  • 2.71%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.08
  • 3.16
  • 7.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.63
  • -3.09
  • 4.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.59
  • -3.62
  • 21.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 40.02
  • 33.98
  • 39.48

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.98
  • 3.39
  • 2.78

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.84
  • 15.90
  • 15.87

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
8,836.78
8,154.85
8.36%
8,553.13
8,123.35
5.29%
7,585.25
8,374.36
-9.42%
8,184.94
7,163.92
14.25%
Expenses
6,502.27
6,395.25
1.67%
6,359.85
6,342.11
0.28%
5,820.90
6,446.13
-9.70%
6,821.93
6,147.13
10.98%
EBITDA
2,334.51
1,759.60
32.67%
2,193.28
1,781.24
23.13%
1,764.35
1,928.23
-8.50%
1,363.01
1,016.79
34.05%
EBIDTM
26.42%
21.58%
25.64%
21.93%
3.55%
3.55%
14.01%
14.01%
Other Income
386.58
201.68
91.68%
255.78
209.35
22.18%
232.95
280.40
-16.92%
102.23
281.53
-63.69%
Interest
26.10
62.96
-58.55%
33.28
83.93
-60.35%
51.95
104.06
-50.08%
51.78
150.03
-65.49%
Depreciation
531.94
546.99
-2.75%
498.60
473.28
5.35%
495.92
457.13
8.49%
575.38
454.05
26.72%
PBT
2,163.05
1,351.33
60.07%
1,917.18
1,433.38
33.75%
15.41
15.41
0.00%
577.44
694.24
-16.82%
Tax
244.94
327.62
-25.24%
-31.20
266.03
-
1.10
1.10
0.00%
83.09
-28.81
-
PAT
1,918.11
1,023.71
87.37%
1,948.38
1,167.35
66.91%
14.31
14.31
0.00%
494.35
723.05
-31.63%
PATM
21.71%
12.55%
22.78%
14.37%
37.11%
37.11%
7.11%
7.11%
EPS
7.72
3.81
102.62%
7.56
4.43
70.65%
1.69
1.69
0.00%
28.29
28.29
0.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
33,160.10
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
Net Sales Growth
4.22%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
 
Cost Of Goods Sold
9,146.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
Gross Profit
24,014.02
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
GP Margin
72.42%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
Total Expenditure
25,504.95
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
Power & Fuel Cost
-
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
% Of Sales
-
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
Employee Cost
-
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
% Of Sales
-
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
Manufacturing Exp.
-
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
% Of Sales
-
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
General & Admin Exp.
-
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
% Of Sales
-
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
Selling & Distn. Exp.
-
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
% Of Sales
-
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
Miscellaneous Exp.
-
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
372.14
% Of Sales
-
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
EBITDA
7,655.15
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
EBITDA Margin
23.09%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
Other Income
977.54
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
Interest
163.11
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
Depreciation
2,101.84
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
PBT
4,673.08
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
Tax
297.93
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
Tax Rate
6.38%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
PAT
4,375.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
PAT before Minority Interest
4,184.25
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
Minority Interest
-190.90
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
PAT Margin
13.19%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
PAT Growth
49.40%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
 
EPS
18.24
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46
11.08
7.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
Share Capital
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
Total Reserves
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
Non-Current Liabilities
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
Secured Loans
257.49
109.47
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
Unsecured Loans
1,771.43
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
Long Term Provisions
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
Current Liabilities
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
Trade Payables
4,093.73
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
Other Current Liabilities
1,891.11
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
Short Term Borrowings
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
Short Term Provisions
4,172.21
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
Total Liabilities
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
Net Block
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
Gross Block
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
Accumulated Depreciation
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
Non Current Assets
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
Capital Work in Progress
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
Non Current Investment
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
Long Term Loans & Adv.
4,060.77
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
Other Non Current Assets
49.24
21.96
50.21
682.18
953.34
103.94
34.20
42.90
18.71
27.75
Current Assets
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
Current Investments
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
Inventories
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
Sundry Debtors
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
Cash & Bank
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
Other Current Assets
2,973.02
1,266.30
891.31
718.25
2,847.64
5,026.16
3,774.42
1,149.11
1,136.55
910.32
Short Term Loans & Adv.
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
Net Current Assets
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
Total Assets
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
PBT
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
Adjustment
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
Changes in Working Capital
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
Cash after chg. in Working capital
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
Net Fixed Assets
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
Net Investments
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
Others
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
Cash from Financing Activity
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
Net Cash Inflow / Outflow
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
Opening Cash & Equivalents
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
Closing Cash & Equivalent
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
59.08
45.79
ROA
6.58%
5.17%
4.24%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
ROE
9.66%
8.05%
6.85%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
ROCE
10.07%
8.68%
8.40%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
Fixed Asset Turnover
1.78
1.92
1.99
1.35
1.34
1.79
1.70
1.51
1.38
1.44
Receivable days
56.22
54.10
53.53
80.78
76.12
48.20
51.72
71.46
71.49
71.57
Inventory Days
48.40
47.84
48.88
76.61
77.46
57.99
63.92
74.22
80.31
80.48
Payable days
63.32
77.81
90.19
77.57
75.24
52.05
56.33
65.15
64.51
51.06
Cash Conversion Cycle
41.30
24.13
12.23
79.82
78.34
54.14
59.31
80.53
87.29
100.98
Total Debt/Equity
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
Interest Cover
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Sun Pharmaceutical Industries recalls products in US market
    16th Mar 2021, 11:58 AM

    The company is recalling Cequa ophthalmic solution, which is used to treat chronic dry eye

    Read More
  • Sun Pharma’s arm acquires stake in WRS Bioproducts Pty
    10th Mar 2021, 15:43 PM

    The company has acquired 428,571 ordinary shares (equivalent to 12.5% fully diluted equity stake)

    Read More
  • Sun Pharma’s arm to acquire stake in WRS Bioproducts Pty
    6th Mar 2021, 10:27 AM

    The company has agreed to acquire by way of allotment to it, 428,571 ordinary shares of WRS Bioproducts Pty

    Read More
  • Sun Pharma launches website for long-term care division in US
    25th Feb 2021, 09:58 AM

    The new website presents the company’s LTC portfolio of alternative formulation products

    Read More
  • Sun Pharma to introduce complete range of Brivaracetam
    23rd Feb 2021, 15:23 PM

    Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks

    Read More
  • Sun Pharma recalls 36,275 cartons of testosterone injection in US for labelling error
    8th Feb 2021, 09:30 AM

    The company initiated the nationwide recall on January 11, 2021

    Read More
  • Sun Pharma reports 2- fold jump in Q3 consolidated net profit
    1st Feb 2021, 16:24 PM

    Total income of the company increased by 10.60% at Rs 9151.73 crore for Q3FY21

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.